» Articles » PMID: 28378417

CCR7 Mediates Human Breast Cancer Cell Invasion, Migration by Inducing Epithelial-mesenchymal Transition and Suppressing Apoptosis Through AKT Pathway

Overview
Journal Cancer Med
Specialty Oncology
Date 2017 Apr 6
PMID 28378417
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokine and the chemokine receptor have a key role in the tumor progress. Here, we supposed that CCR7 might induce the invasion, migration, and epithelial-mesenchymal transition (EMT) process of breast cancer. In this research, human breast cancer MCF-7 and MDA-MB-231cells were treated with CCL19 and small-interfering RNA (CCR7 siRNA) for activation and inhibition of CCR7, respectively. Cell invasion and transwell assays were used to detect the effect of CCR7 on invasion and migration. The results demonstrated that CCL19 mediated cell invasion and migration by inducing the EMT, with downregulation of E-cadherin and up-regulation of N-cadherin and vimentin levels. On the other hand, knockdown of CCR7 revealed the changes compared with CCL19 group and the control group. Knockdown of CCR7 inhibits CCL19-induced breast cancer cell proliferation, the cell cycle, migration, invasion and EMT. Moreover, we demonstrated that CCL19-induced AKT phosphorylation; however, CCR7 siRNA suppressed CCL19-induced AKT phosphorylation, a key regulator of tumor metastasis. In conclusion, all findings demonstrated that CCL19/CCR7 axis regulated EMT progress in breast cancer cells and mediated the tumor cell invasion and migration process via activation of AKT signal pathway. Our results suggested that CCR7 may regard as a therapeutic target for the breast cancer treatment.

Citing Articles

The Use of Biologics for Targeting GPCRs in Metastatic Cancers.

McBrien C, OConnell D BioTech (Basel). 2025; 14(1).

PMID: 39982274 PMC: 11843943. DOI: 10.3390/biotech14010007.


Identifying epithelial-mesenchymal transition-related genes as prognostic biomarkers and therapeutic targets of hepatocellular carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data.

Chen C, Wang S, Tang Y, Liu H, Tu D, Su B Transl Cancer Res. 2024; 13(8):4257-4277.

PMID: 39262476 PMC: 11384925. DOI: 10.21037/tcr-24-521.


Modulation of esophageal squamous cell carcinoma progression: the impact of CCR7 on JAK2/STAT3 signaling pathway.

Zhang X, An Y, Mai D, Huang W, Zeng W Discov Oncol. 2024; 15(1):421.

PMID: 39254762 PMC: 11387284. DOI: 10.1007/s12672-024-01289-2.


Immune Cell Migration to Cancer.

Ryan A, Kim M, Lim K Cells. 2024; 13(10.

PMID: 38786066 PMC: 11120175. DOI: 10.3390/cells13100844.


CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers.

Gu Q, Zhou S, Chen C, Wang Z, Xu W, Zhang J Aging (Albany NY). 2023; 15(21):12369-12387.

PMID: 37944262 PMC: 10683612. DOI: 10.18632/aging.205184.


References
1.
Raap M, Antonopoulos W, Dammrich M, Christgen H, Steinmann D, Langer F . High frequency of lobular breast cancer in distant metastases to the orbit. Cancer Med. 2014; 4(1):104-11. PMC: 4312124. DOI: 10.1002/cam4.331. View

2.
Lian S, Shao Y, Liu H, He J, Lu W, Zhang Y . PDK1 induces JunB, EMT, cell migration and invasion in human gallbladder cancer. Oncotarget. 2015; 6(30):29076-86. PMC: 4745712. DOI: 10.18632/oncotarget.4931. View

3.
Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M . CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer. Int J Oncol. 2009; 35(1):19-24. DOI: 10.3892/ijo_00000308. View

4.
Schimanski C, Bahre R, Gockel I, Junginger T, Simiantonaki N, Biesterfeld S . Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep. 2006; 16(1):109-13. View

5.
El-Mezayen H, Metwally F, Darwish H . A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer. Tumour Biol. 2013; 35(3):2759-67. DOI: 10.1007/s13277-013-1366-y. View